Skip to main content
. Author manuscript; available in PMC: 2019 Dec 4.
Published in final edited form as: Nat Immunol. 2019 Jun 3;20(7):835–851. doi: 10.1038/s41590-019-0400-7

Figure 5: LINK-A represses PKA-dependent TRIM71 phosphorylation.

Figure 5:

a, Measurement of cAMP concentration in MMTV-cre normal mammary gland, MMTV-PyVT or MMTV-Tg(LINK-A) tumor lysates (n.s., p>0.05, ***p<0.001). Results are mean ± s.e.m. of n=4 animals per experimental condition, P values were determined by one-way ANOVA. b, Percentage of modified vs. total number of peptides harboring indicated residues of PKA catalytic unit α (left) or TRIM71 (right) in MMTV-cre mammary gland, MMTV-PyVT or MMTV-Tg(LINK-A) tumors. c, Annotated MS/MS spectrum assigned to the TRIM71 peptide MApSFPETDFQICLLCK acquired from analysis of tryptic digest by high-sensitivity LC-MS/MS on an Orbitrap Elite high-resolution mass spectrometer. d and e, Pearson correlation between immunoblotting staining of p-PKA C-α (Thr197) (d) or p-TRIM71 (Ser3) (e) and LINK-A copy number of human TNBC tissues upon Pembrolizumab treatment (n=12 tissues). f, Percentage of modified vs. total number of peptides harboring indicated residues of Rb (top) or p53 (bottom) in MMTV-cre mammary gland, MMTV-PyVT or MMTV-Tg(LINK-A) tumors. g-i, Representative images (g) and statistical analysis (h and i) of immunohistochemistry staining using indicated antibodies of Tg(LINK-A) normal mammary gland and MMTV-Tg(LINK-A) tumors. Scale bars (g): 100 μm. (h and i) (***p<0.001). Results are mean ± s.d. of n=6 animals per experimental condition. P values were determined by unpaired two-tailed Student’s t test.